Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Volrustomig Priming Regimens Exploratory Phase II Platform Study (eVOLVE-01)

28. september 2026 opdateret af: AstraZeneca

Et åbent fase II-studie til evaluering af sikkerhed, tolerabilitet, farmakokinetik, immunogenicitet og antitumoraktivitet af Volrustomig-primingregimer i kombination med andre anticancermidler hos deltagere med solide tumorer (eVOLVE-01)

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This Phase II, platform, open-label, multicenter study will evaluate the efficacy, safety, and tolerability of volrustomig in combination with anticancer drugs in various solid tumor types.

This platform study currently includes 2 substudies:

Substudy 1: metastatic non-small cell lung cancer (mNSCLC) (non-squamous [NSQ]). Participants will be randomized in two treatment arms: Arm 1A and Arm 1B.

Substudy 2: mNSCLC (squamous [SQ] or NSQ). Participants will enroll to the Arm 2A only.

All arms will test a volrustomig dosing in combination with chemotherapy.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

194

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Los Angeles, California, Forenede Stater, 90067
        • Research Site
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27514
        • Research Site
      • Bois-Guillaume, Frankrig, 76031
        • Research Site
      • Caen, Frankrig, 14076
        • Research Site
      • Dijon, Frankrig, 21079
        • Research Site
      • Montpellier, Frankrig, 34070
        • Research Site
      • Batumi, Georgien, 6010
        • Research Site
      • Tbilisi, Georgien, 0144
        • Research Site
      • Tbilisi, Georgien, 0112
        • Research Site
      • Tbilisi, Georgien, '0159
        • Research Site
      • Tbilisi, Georgien, 186
        • Research Site
      • Tbilisi, Georgien, 0114
        • Research Site
      • Athens, Grækenland, 115 27
        • Research Site
      • Athens, Grækenland, 12462
        • Research Site
      • Elaiones, Grækenland, 546 23
        • Research Site
      • Piraeus, Grækenland, 185 47
        • Research Site
      • Thessaloniki, Grækenland, 57001
        • Research Site
      • Genoa, Italien, 16132
        • Research Site
      • Meldola, Italien, 47014
        • Research Site
      • Milan, Italien, 20133
        • Research Site
      • Naples, Italien, 80131
        • Research Site
      • Orbassano, Italien, 10043
        • Research Site
      • Perugia, Italien, 06132
        • Research Site
      • Rozzano, Italien, 20089
        • Research Site
      • Udine, Italien, 33100
        • Research Site
      • Verona, Italien, 37134
        • Research Site
      • Beijing, Kina, 100730
        • Research Site
      • Hangzhou, Kina, 310014
        • Research Site
      • Jinan, Kina, 250013
        • Research Site
      • Yantai, Kina, 264000
        • Research Site
      • Zhengzhou, Kina, 450000
        • Research Site
      • Kuala Lumpur, Malaysia, 59100
        • Research Site
      • Kuching, Malaysia, 93586
        • Research Site
      • Perai, Malaysia, 13700
        • Research Site
      • Lisbon, Portugal, 1649-035
        • Research Site
      • Lisbon, Portugal, 1169-050
        • Research Site
      • Lisbon, Portugal, 1400-038
        • Research Site
      • Porto, Portugal, 4099-001
        • Research Site
      • Cluj-Napoca, Rumænien, 400641
        • Research Site
      • Craiova, Rumænien, 200542
        • Research Site
      • Floreşti, Rumænien, 407280
        • Research Site
      • Geneva, Schweiz, 1205
        • Research Site
      • Lausanne, Schweiz, 1011
        • Research Site
      • Winterthur, Schweiz, 8401
        • Research Site
      • Zurich, Schweiz, 8091
        • Research Site
      • Belgrade, Serbien, 11000
        • Research Site
      • A Coruña, Spanien, 15009
        • Research Site
      • Alcorcón, Spanien, 28922
        • Research Site
      • Barcelona, Spanien, 08041
        • Research Site
      • Madrid, Spanien, 28041
        • Research Site
      • Málaga, Spanien, 29004
        • Research Site
      • Pamplona, Spanien, 31008
        • Research Site
      • Santander, Spanien, 39008
        • Research Site
      • Santiago de Compostela, Spanien, 15706
        • Research Site
      • Valencia, Spanien, 46026
        • Research Site
      • Valencia, Spanien, 46015
        • Research Site
      • Seongnam, Sydkorea, 13620
        • Research Site
      • Seoul, Sydkorea, 03722
        • Research Site
      • Suwon, Sydkorea, 16247
        • Research Site
      • Changhua, Taiwan, 50006
        • Research Site
      • New Taipei City, Taiwan, 23561
        • Research Site
      • Taipei, Taiwan, 106
        • Research Site
      • Taipei, Taiwan, 110
        • Research Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 130 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
  • Life expectancy greater than or equal to (>=) 12 weeks.
  • Adequate organ and bone marrow function.
  • Body weight greater than (>) 35 kilograms (kg) at screening and at randomization.
  • Histologically or cytologically documented NSQ NSCLC in substudy 1 and SQ or NSQ mNSCLC in substudy 2.
  • Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
  • Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
  • At least one measurable lesion not previously irradiated that can be accurately measured at baseline as >= 10 millimeter (mm) in the longest diameter.

Key Exclusion Criteria:

  • Spinal cord compression.
  • History of primary active immunodeficiency.
  • Active or prior documented autoimmune or inflammatory disorders.
  • Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
  • Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment.
  • Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Substudy 1: Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed

Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed.

Participants will receive volrustomig via intravenous (IV) infusion.

Andre navne:
  • MEDI5752

Participants will receive carboplatin via IV infusion.

Participants will receive pemetrexed via IV infusion.

Eksperimentel: Substudy 1: Arm 1B: Volrustomig dose regimen 2 + Carboplatin and Pemetrexed

Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed.

Participants will receive volrustomig via intravenous (IV) infusion.

Andre navne:
  • MEDI5752

Participants will receive carboplatin via IV infusion.

Participants will receive pemetrexed via IV infusion.

Eksperimentel: Substudy 2: Arm 2A: Volrustomig dose regimen 2 +Ramucirumab + Carboplatin + Pemetrexed or Paclitaxel

Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with ramucirumab and histology-specific chemotherapy (carboplatin+ either pemetrexed or paclitaxel).

Participants will receive volrustomig via intravenous (IV) infusion.

Andre navne:
  • MEDI5752

Participants will receive carboplatin via IV infusion.

Participants will receive pemetrexed via IV infusion.

Participants will receive ramucirumab via IV infusion.

Participants will receive paclitaxel via IV infusion.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: From screening (Days -28 to Day -1) up to 2 year 10 months

The safety and tolerability of volrustomig in combination with other anticancer drugs in participants with specified solid tumors will be assessed.

From screening (Days -28 to Day -1) up to 2 year 10 months
Confirmed Objective Response rate (ORR)
Tidsramme: Up to 2 year 10 months

ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).

Up to 2 year 10 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Disease Control Rate (DCR)
Tidsramme: Up to 2 year 10 months

DCR is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) after the date of randomization or first dose.

Up to 2 year 10 months
Duration of Response (DOR)
Tidsramme: Up to 2 year 10 months

DOR is defined as the time from the date of first documented response until the date of documented progression or death due to any cause (in the absence of progression).

Up to 2 year 10 months
Progression Free Survival (PFS)
Tidsramme: Up to 2 year 10 months

PFS is defined as the time from randomization or first dose until radiological progression or death due to any cause (in the absence of progression).

Up to 2 year 10 months
Overall Survival (OS)
Tidsramme: Up to 2 year 10 months

OS is defined as the time from randomization or first dose until the date of death due to any cause.

Up to 2 year 10 months
Serum Concentration of Volrustomig
Tidsramme: Up to 2 year 10 months

The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed.

Up to 2 year 10 months
Trough concentration (Ctrough)
Tidsramme: Up to 2 year 10 months

The trough concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed.

Up to 2 year 10 months
Maximum Observed Concentration (Cmax)
Tidsramme: Up to 2 year 10 months

The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed.

Up to 2 year 10 months
Area Under the Curve (AUC)
Tidsramme: Up to 2 year 10 months

The AUC concentrations of volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed.

Up to 2 year 10 months
Number of Participants with Positive Antidrug Antibodies (ADAs)
Tidsramme: Up to 2 year 10 months

The incidence of ADAs against volrustomig or other anticancer agents in serum will be assessed.

Up to 2 year 10 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

27. august 2024

Primær færdiggørelse (Anslået)

30. juli 2027

Studieafslutning (Anslået)

30. juli 2027

Datoer for studieregistrering

Først indsendt

4. juni 2024

Først indsendt, der opfyldte QC-kriterier

4. juni 2024

Først opslået (Faktiske)

7. juni 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers can request access to anonymized individual patient-leveldata from AstraZeneca group of companies sponsored clinical trials via therequest portal Vivli.org. All requests will be evaluated as per the AZ disclosurecommitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicates that AZ are accepting requests for IPD, but this does not mean allrequests will be approved.

IPD-delingstidsramme

AstraZeneca will meet or exceed data availability as per the commitment smade to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-delingsadgangskriterier

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure researchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .